# 1st Gen Model Celgene Corporation Pharmaceutical preparations
- $133.85Last close price
at 26-jun-2017 -
Subscribe >>
Deal exit on
June 27, 2017 Deal entry on
June 27, 2017 - 3.48%Expected margin
- 70.77% successful of 65 deals
CELG
Model's trade recommendations -11.16% Return for period
9.86% Annual return
$104.87B Market Cap
β 1.82
CELG
Model (following trade recommendations)CELG
Underlying stockS&P 500
Index- STRONG BUY Analysts consensus recommendation
Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Celgene Corporation (CELG) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 2, 2015.
Market data for CELG model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
| Float | 773M |
| P/E | 23.94 |
| Shares Outstanding | 781M |
| % Held by Insiders | 0.95% |
| % Held by Institutions | 78.26% |
| EPS (last reported FY) | $5.18 |
| EPS (last reported Q) | $1.53 |
| EPS, estimated (last reported Q) | $1.47 |
| Total revenues | $11 B |
| Net income | $2 B |